CNBC April 4, 2024
Key Points
– A highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson’s disease, too.
– In a mid-stage trial, an older diabetes treatment called lixisenatide helped slow the progression of motor disability in a small group of patients with the debilitating condition.
– The drug, made by Sanofi, is a GLP-1 like Novo Nordisk’s blockbuster diabetes injection Ozempic and weight loss counterpart Wegovy
A highly popular class of drugs for diabetes and obesity is showing early potential to help patients with Parkinson’s disease, too.
An older diabetes treatment called lixisenatide helped slow the progression of motor disability after 12 months in patients at an early stage of the...
Today's Sponsors
Today's Sponsor